| Literature DB >> 32440406 |
David Perrault1, Cindy Kin2, Derrick C Wan1, Natalie Kirilcuk2, Andrew Shelton2, Arash Momeni1.
Abstract
BACKGROUND: Abdominoperineal resection (APR) and pelvic exenteration continue to be common procedures for the treatment of colorectal malignancy. The workhorse flap for reconstruction in these instances has been the vertical rectus abdominis myocutaneous flap. The associated donor site morbidity, however, cannot be ignored. Here, we provide a review of the literature and present the senior author's (A.M.) experience using the pedicled anterolateral thigh (ALT) flap for reconstruction of soft tissue defects following APR and pelvic exenteration.Entities:
Year: 2020 PMID: 32440406 PMCID: PMC7209827 DOI: 10.1097/GOX.0000000000002733
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Fig. 1.Perineal and type IB vaginal defect.
Fig. 2.Large soft tissue defect following pelvic exenteration.
Fig. 3.A tunnel is created under the rectus femoris and sartorius muscles. Medial to the sartorius muscle, the plane of dissection transitions to the subcutaneous plane.
Fig. 4.Tension-free position of the vascular pedicle following flap transfer.
Fig. 5.Pre- and postoperative image of a perineal and type IB vaginal defect followed by perineal and vaginal reconstruction with a pedicled ALT flap.
Fig. 6.Pre- and postoperative image of a perineal defect following pelvic exenteration and soft tissue reconstruction with a pedicled ALT flap (without reconstruction of a neovagina).
Patient Demographics
| Patient | Age (y) | Gender | BMI (kg/m2) | Diagnosis | Comorbidities | Radiation Therapy | Oncologic Procedure |
|---|---|---|---|---|---|---|---|
| 1 | 66 | M | 24.3 | Rectal cancer | DM | Yes | APR |
| 2 | 42 | M | 24.9 | Crohn’s disease | No | APR | |
| 3 | 58 | F | 26.3 | Recurrent anal cancer | Yes | APR + posterior vaginectomy | |
| 4 | 82 | M | 22.3 | Rectal cancer | COPD | Yes | APR |
| 5 | 84 | M | 24.7 | Rectal cancer | HTN, CAD, DM | Yes | APR |
| 6 | 66 | M | 24.4 | Rectal cancer | Yes | APR | |
| 7 | 48 | M | 28.3 | Recurrent rectal cancer | HTN, HLP | Yes | APR |
| 8 | 67 | M | 23.1 | Recurrent rectal cancer | Yes | APR | |
| 9 | 69 | F | 25.4 | Rectal cancer | HTN, HLP, DM | Yes | APR + posterior vaginectomy |
| 10 | 67 | M | 29.1 | Rectal cancer | DM | Yes | APR |
| 11 | 72 | M | 33.7 | Rectal cancer | HTN | Yes | Pelvic exenteration |
| 12 | 60 | F | 24.1 | Recurrent anal cancer | Yes | Pelvic exenteration | |
| 13 | 23 | M | 18.9 | Crohn’s disease | No | APR | |
| 14 | 58 | F | 38.3 | Recurrent anal cancer | HTN | Yes | Pelvic exenteration |
| 15 | 73 | M | 24.7 | Rectal cancer | CAD, COPD, HLP, HTN | Yes | APR |
| 16 | 71 | M | 26.7 | Rectal cancer | DM, HLP, HTN | Yes | APR |
| 17 | 84 | F | 25.7 | Rectal cancer | HTN, GERD, CAD | Yes | APR |
| 18 | 54 | M | 26.7 | Recurrent anal cancer | Yes | APR | |
| 19 | 53 | F | 24.2 | Recurrent anal cancer | Hepatitis C | Yes | APR + posterior vaginectomy |
| 20 | 70 | F | 22.9 | Paget’s disease | HTN, CAD, DM | Yes | APR |
| 21 | 48 | M | 26.5 | Rectal cancer | Yes | APR | |
| 22 | 33 | M | 24.3 | Crohn’s disease | No | APR | |
| 23 | 49 | M | 28.1 | Crohn’s disease | DM | No | APR |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; F, female; GERD, gastroesophageal reflux disease; HLP, hyperlipidemia; HTN, hypertension; M, male.
Patient Demographics (Summary)
| N = 23 | |
|---|---|
| Median age (IQR), y | 66 (49–71) |
| Female, n (%) | 7 (30.4) |
| Median BMI (IQR) | 24.9 (24.2–26.7) |
| BMI > 30, n (%) | 2 (8.7) |
| Primary disease, n (%) | |
| Rectal cancer | 13 (56.5) |
| Anal cancer | 5 (21.7) |
| Crohn’s disease | 4 (17.4) |
| Paget’s disease | 1 (4.3) |
| Comorbidities | |
| Diabetes mellitus | 7 (30.4) |
| Hypertension | 9 (39.1) |
| Coronary artery disease | 4 (17.4) |
| Chronic obstructive pulmonary disease | 2 (8.7) |
| Hyperlipidemia | 4 (17.4) |
| Hepatitis C | 1 (4.3) |
| Radiation therapy, n (%) | 19 (82.6) |
IQR, inter-quartile range.
Postoperative Complications
| Complications | N (%) |
|---|---|
| Patients with complications | 9 (39.1) |
| Major complications | 2 (8.7) |
| Sacral osteomyelitis | 1 (4.4) |
| Donor site seroma | 1 (4.4) |
| Urinary leak resulting in perineal wound dehiscence | 1 (4.4) |
| Minor complications | 9 (39.1) |
| Perineal wound dehiscence | 6 (26.1) |
| DVT | 1 (4.3) |
| Leg weakness (temporary) | 2 (8.7) |
Some patients experienced more than one complication.
DVT, deep vein thrombosis.
Comparison of Patient Demographics and Comorbidities for Wound Complications
| No Complication (N = 14) | Complication (N = 9) | ||
|---|---|---|---|
| Age, n (%) | 0.214 | ||
| <65 | 5 (35.7) | 6 (66.7) | |
| >65 | 9 (64.3) | 3 (33.3) | |
| Gender, n (%) | 0.363 | ||
| Female | 3 (21.4) | 4 (44.4) | |
| Male | 11 (78.6) | 5 (55.6) | |
| BMI, n (%) | 0.1423 | ||
| <30 | 14 (100) | 7 (77.8) | |
| >30 | 0 (0) | 2 (22.2) | |
| Diabetes mellitus, n (%) | 0.657 | ||
| No | 9 (64.3) | 7 (77.8) | |
| Yes | 5 (35.7) | 2 (22.2) | |
| Hypertension, n (%) | >0.999 | ||
| No | 9 (64.3) | 5 (55.6) | |
| Yes | 5 (35.7) | 4 (44.4) | |
| CAD, n (%) | >0.999 | ||
| No | 12 (85.7) | 7 (77.8) | |
| Yes | 2 (14.3) | 2 (22.2) | |
| COPD, n (%) | 0.502 | ||
| No | 12 (85.7) | 9 (100) | |
| Yes | 2 (14.3) | 0 (0) | |
| HLP, n (%) | 0.127 | ||
| No | 10 (71.4) | 9 (100) | |
| Yes | 4 (28.6) | 0 (0) | |
| Hepatitis C, n (%) | 0.391 | ||
| No | 14 (100) | 8 (88.9) | |
| Yes | 0 (0) | 1 (11.1) | |
| Rectal cancer, n (%) | 0.102 | ||
| No | 4 (28.6) | 6 (66.7) | |
| Yes | 10 (71.4) | 3 (33.3) | |
| Anal cancer, n (%) | 0.343 | ||
| No | 12 (85.7) | 6 (66.7) | |
| Yes | 2 (14.3) | 3 (33.3) | |
| Paget’s disease, n (%) | >0.999 | ||
| No | 13 (92.8) | 9 (100) | |
| Yes | 1 (7.1) | 0 (0) | |
| Radiation therapy, n (%) | 0.26 | ||
| No | 1 (7.1) | 3 (33.3) | |
| Yes | 13 (92.8) | 6 (66.7) |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HLP, hyperlipidemia.